Discussed here is the recent law in Massachusetts relative to gifts, etc. just recently passed. Being the CEO of BIO, the biotech industry trade group, of course there's an interest in not having funds diminished, but also addresses the interest of the public. With all the recent Pharma/biotech mergers, buyouts, etc. is this the same old game in place with the exception of Biotech now more or less ruling the roost where the drug companies had full reign at one time?
Investments and funds to keep research and development are important and vital to keep the system going and alive. As the field continues to grow and clinical trials with smaller groups make information more readily available, faster than the methodologies have allowed in the past, it will be interesting to see how this evolves. With DNA testing, which I am assuming every test, no matter where it is done, should be the same or very similar to one done at another facility given the same set of circumstances, how is the competition going to factor here. Will all genomics tests be equal? It's too early in the game to go there yet, but it will go there at some point in time.
In the meantime, Biotech continues to lobby our Congressmen. The FDA is mentioned here with needed the best scientists around, and nobody can question that decision for one minute, but deep in the heart of Congress where decisions are made, we still have many who are still behind the times as recent members of Congress have stated openly themselves, so how this all plays out remains to be seen. There's no secrecy anymore and transparency is the name of the game.
"What goes on the Internet, stays on the Internet". BD
That's the view of Jim Greenwood, CEO of BIO, the biotech industry trade group. Unfortunately, he told us during a recent chat at Health Blog HQ, bad policy comes more easily than good policy.
Health Blog : BIO Chief on the Wisdom of Giving Money to Democrats
0 comments :
Post a Comment